Prenatal management of fetal anemia due to pyruvate kinase deficiency: A case report

Transfusion. 2023 Jan;63(1):257-262. doi: 10.1111/trf.17177. Epub 2022 Nov 8.

Abstract

Background: Pyruvate Kinase (PK) deficiency is the most common enzyme defect of glycolysis, leading to congenital hemolytic anemia, which can occur during the neonatal period.

Study design and methods: We report the prenatal management of fetal anemia related to PK deficiency in a family with a severe proband.

Results: The couple had a first child born with hydrops, whose PK deficiency was diagnosed at 18 months of life. He was treated with allogeneic bone marrow transplantation. The second child was free from disease. For the third pregnancy, the amniocentesis revealed a PK deficiency. Weekly ultrasound monitoring of the middle cerebral artery velocity allowed the detection of severe fetal anemia. Two intrauterine red blood cell transfusions (IUTs) were performed, raising the fetal hemoglobin from 6.6 to 14.5 g/dl at 28 weeks' gestation and from 8.9 to 15.3 g/dl at 31 weeks. A hematopoietic stem cell allograft was discussed prenatally but not chosen, as it would not have significantly changed the perinatal prognosis. The patient delivered a 2730 g girl at 37 weeks, with hemoglobin of 13.6 g/dl. The child presented with neonatal jaundice treated with phototherapy and received postnatal transfusions.

Discussion: When a proband is identified in a family, fetal investigation is warranted, to set up third-trimester ultrasound surveillance and perinatal management. In case of fetal severe anemia of unknown etiology, the workup on fetal blood sampling before IUT should comprise the search for erythrocytes enzymopathies, such as PK deficiency. IUTs allow safer full-term delivery in cases with PK deficiency.

Keywords: congenital hemolytic anemia; hematopoietic stem cell transplantation; intrauterine transfusion; pregnancy; prenatal diagnosis; pyruvate kinase deficiency.

Publication types

  • Case Reports

MeSH terms

  • Anemia* / etiology
  • Anemia* / therapy
  • Anemia, Hemolytic, Congenital Nonspherocytic* / complications
  • Anemia, Hemolytic, Congenital Nonspherocytic* / diagnosis
  • Anemia, Hemolytic, Congenital Nonspherocytic* / therapy
  • Blood Transfusion, Intrauterine / adverse effects
  • Child
  • Female
  • Fetal Diseases* / diagnostic imaging
  • Fetal Diseases* / therapy
  • Humans
  • Infant, Newborn
  • Male
  • Pregnancy
  • Pyruvate Kinase

Substances

  • Pyruvate Kinase

Supplementary concepts

  • Pyruvate Kinase Deficiency of Red Cells